32
Participants
Start Date
January 13, 2004
Primary Completion Date
August 31, 2012
Study Completion Date
June 30, 2014
PEG-interferon alfa-2b
Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
UPMC Cancer Centers, Pittsburgh
West Virginia University Health Sciences Center - Charleston, Charleston
Lakeland Regional Cancer Center at Lakeland Regional Medical Center, Lakeland
UAB Comprehensive Cancer Center, Birmingham
MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland
Borgess Medical Center, Kalamazoo
Bronson Methodist Hospital, Kalamazoo
Gundersen Lutheran Center for Cancer and Blood, La Crosse
Hinsdale Hematology Oncology Associates, Hinsdale
Community Hospital of Ottawa, Ottawa
Illinois Valley Community Hospital, Peru
Perry Memorial Hospital, Princeton
Galesburg Clinic, PC, Galesburg
McDonough District Hospital, Macomb
Graham Hospital, Canton
Eureka Community Hospital, Eureka
Cancer Treatment Center at Pekin Hospital, Pekin
Proctor Hospital, Peoria
CCOP - Illinois Oncology Research Association, Peoria
Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria
Methodist Medical Center of Illinois, Peoria
OSF St. Francis Medical Center, Peoria
St. Joseph Medical Center, Bloomington
BroMenn Regional Medical Center, Normal
Community Cancer Center, Normal
Memorial Hospital, Carthage
Decatur Memorial Hospital Cancer Care Institute, Decatur
Mason District Hospital, Havana
Swedish-American Regional Cancer Center, Rockford
West Michigan Cancer Center, Kalamazoo
Summa Center for Cancer Care at Akron City Hospital, Akron
Aultman Cancer Center at Aultman Hospital, Canton
National Cancer Institute (NCI)
NIH
Eastern Cooperative Oncology Group
NETWORK